Herceptin’s (trastuzumab) use in breast cancer highlights the importance of an appropriate Her2/neu evaluation to ensure accurate identification of patients eligible for the anti-Her2 targeted therapies in gastric cancer. Here, ERBB2 is linked to gastric cancer.